Terms: = Breast cancer AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Treatment
24 results:
1. The bap1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
[TBL] [Abstract] [Full Text] [Related]
2. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a bap1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract] [Full Text] [Related]
3. Tumor Profiles of Late Presentation Uveal Ring Melanoma With Novel Characteristics - A Case Series.
Lim JZ; Crawford AZ; McGhee CNJ
Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):44. PubMed ID: 37889509
[TBL] [Abstract] [Full Text] [Related]
4. Targeting bap1 with small compound inhibitor for colon cancer treatment.
Kang M; Park SG; Lee SA; Kim S; Lee D; Shirbhate ME; Youn SY; Kim KM; Cha SS; Kwon J
Sci Rep; 2023 Feb; 13(1):2264. PubMed ID: 36754982
[TBL] [Abstract] [Full Text] [Related]
5. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Li Y; Lih TM; Dhanasekaran SM; Mannan R; Chen L; Cieslik M; Wu Y; Lu RJ; Clark DJ; Kołodziejczak I; Hong R; Chen S; Zhao Y; Chugh S; Caravan W; Naser Al Deen N; Hosseini N; Newton CJ; Krug K; Xu Y; Cho KC; Hu Y; Zhang Y; Kumar-Sinha C; Ma W; Calinawan A; Wyczalkowski MA; Wendl MC; Wang Y; Guo S; Zhang C; Le A; Dagar A; Hopkins A; Cho H; Leprevost FDV; Jing X; Teo GC; Liu W; Reimers MA; Pachynski R; Lazar AJ; Chinnaiyan AM; Van Tine BA; Zhang B; Rodland KD; Getz G; Mani DR; Wang P; Chen F; Hostetter G; Thiagarajan M; Linehan WM; Fenyö D; Jewell SD; Omenn GS; Mehra R; Wiznerowicz M; Robles AI; Mesri M; Hiltke T; An E; Rodriguez H; Chan DW; Ricketts CJ; Nesvizhskii AI; Zhang H; Ding L;
Cancer Cell; 2023 Jan; 41(1):139-163.e17. PubMed ID: 36563681
[TBL] [Abstract] [Full Text] [Related]
6. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract] [Full Text] [Related]
7. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z
Front Immunol; 2022; 13():925618. PubMed ID: 35898502
[TBL] [Abstract] [Full Text] [Related]
8. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline bap1 Mutations.
Carbone M; Pass HI; Ak G; Alexander HR; Baas P; Baumann F; Blakely AM; Bueno R; Bzura A; Cardillo G; Churpek JE; Dianzani I; De Rienzo A; Emi M; Emri S; Felley-Bosco E; Fennell DA; Flores RM; Grosso F; Hayward NK; Hesdorffer M; Hoang CD; Johansson PA; Kindler HL; Kittaneh M; Krausz T; Mansfield A; Metintas M; Minaai M; Mutti L; Nielsen M; O'Byrne K; Opitz I; Pastorino S; Pentimalli F; de Perrot M; Pritchard A; Ripley RT; Robinson B; Rusch V; Taioli E; Takinishi Y; Tanji M; Tsao AS; Tuncer AM; Walpole S; Wolf A; Yang H; Yoshikawa Y; Zolondick A; Schrump DS; Hassan R
J Thorac Oncol; 2022 Jul; 17(7):873-889. PubMed ID: 35462085
[TBL] [Abstract] [Full Text] [Related]
9. bap1-defficient breast cancer in a patient with bap1 cancer syndrome.
Blatnik A; Ribnikar D; Šetrajčič Dragoš V; Novaković S; Stegel V; Grčar Kuzmanov B; Boc N; Perić B; Škerl P; Klančar G; Krajc M
Breast Cancer; 2022 Sep; 29(5):921-927. PubMed ID: 35381901
[TBL] [Abstract] [Full Text] [Related]
10. bap1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Wang F; Luo M; Qu H; Cheng Y
FEBS Open Bio; 2021 May; 11(5):1497-1503. PubMed ID: 33529461
[TBL] [Abstract] [Full Text] [Related]
11. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
[TBL] [Abstract] [Full Text] [Related]
12. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract] [Full Text] [Related]
13. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
Tang J; Li Y; Sang Y; Yu B; Lv D; Zhang W; Feng H
Oncogene; 2018 Aug; 37(34):4723-4734. PubMed ID: 29760406
[TBL] [Abstract] [Full Text] [Related]
15. Novel therapeutic strategies and targets in advanced uveal melanoma.
Chua V; Aplin AE
Curr Opin Oncol; 2018 Mar; 30(2):134-141. PubMed ID: 29206651
[TBL] [Abstract] [Full Text] [Related]
16. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract] [Full Text] [Related]
17. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract] [Full Text] [Related]
18. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
Gillon P; Touati N; Breton-Callu C; Slaets L; Cameron D; Bonnefoi H
Eur J Cancer; 2017 Jul; 79():226-234. PubMed ID: 28527420
[TBL] [Abstract] [Full Text] [Related]
19. Uveal melanoma: From diagnosis to treatment and the science in between.
Chattopadhyay C; Kim DW; Gombos DS; Oba J; Qin Y; Williams MD; Esmaeli B; Grimm EA; Wargo JA; Woodman SE; Patel SP
Cancer; 2016 Aug; 122(15):2299-312. PubMed ID: 26991400
[TBL] [Abstract] [Full Text] [Related]
20. Connecting molecular pathways to hereditary cancer risk syndromes.
Testa JR; Malkin D; Schiffman JD
Am Soc Clin Oncol Educ Book; 2013; ():81-90. PubMed ID: 23714463
[TBL] [Abstract] [Full Text] [Related]
[Next]
